skip to content
Covid-19 virus
COVID-19 Resources

Reliable information about the coronavirus (COVID-19) is available from the World Health Organization (current situation, international travel). Numerous and frequently-updated resource results are available from this WorldCat.org search. OCLC’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle coronavirus issues in their communities.

Image provided by: CDC/ Alissa Eckert, MS; Dan Higgins, MAM
Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/Beta-Thalassemia, sickle cell/Hemoglobin C disease and severe combined immunodeficiency : costs and cost analysis Preview this item
ClosePreview this item
Checking...

Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/Beta-Thalassemia, sickle cell/Hemoglobin C disease and severe combined immunodeficiency : costs and cost analysis

Author: Institute of Health Economics,
Publisher: Edmonton, AB, Canada : Institute of Health Economics, March 2016.
Series: Alberta STE report.
Edition/Format:   eBook : Document : English
Summary:
This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Institute of Health Economics,
ISBN: 9781926929651 1926929659
OCLC Number: 1048246242
Description: 1 online resource (1 PDF file (xxviii, 256 pages)) : illustrations.
Series Title: Alberta STE report.
Responsibility: Institute of Health Economics.

Abstract:

This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


\n\n

Primary Entity<\/h3>\n
<http:\/\/www.worldcat.org\/oclc\/1048246242<\/a>> # Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell\/Beta-Thalassemia, sickle cell\/Hemoglobin C disease and severe combined immunodeficiency : costs and cost analysis<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Book<\/a>, schema:MediaObject<\/a>, schema:CreativeWork<\/a> ;\u00A0\u00A0\u00A0\nlibrary:oclcnum<\/a> \"1048246242<\/span>\" ;\u00A0\u00A0\u00A0\nlibrary:placeOfPublication<\/a> <http:\/\/id.loc.gov\/vocabulary\/countries\/abc<\/a>> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/neonatal_screening_economics<\/a>> ; # Neonatal Screening--economics<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Place\/alberta<\/a>> ; # Alberta.<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/dried_blood_spot_testing_economics<\/a>> ; # Dried Blood Spot Testing--economics<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/technology_assessment_biomedical<\/a>> ; # Technology Assessment, Biomedical<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/brain_diseases_metabolic_inborn_diagnosis<\/a>> ; # Brain Diseases, Metabolic, Inborn--diagnosis<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/anemia_hemolytic_congenital_diagnosis<\/a>> ; # Anemia, Hemolytic, Congenital--diagnosis<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/cost_benefit_analysis<\/a>> ; # Cost-Benefit Analysis<\/span>\n\u00A0\u00A0\u00A0\nschema:bookFormat<\/a> schema:EBook<\/a> ;\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Organization\/institute_of_health_economics<\/a>> ; # Institute of Health Economics,<\/span>\n\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2016<\/span>\" ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"This STE report examines the safety, screening accuracy, therapeutic efficacy\/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell\/beta-thalassemia, sickle cell\/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:exampleOfWork<\/a> <http:\/\/worldcat.org\/entity\/work\/id\/5375842389<\/a>> ;\u00A0\u00A0\u00A0\nschema:inLanguage<\/a> \"en<\/span>\" ;\u00A0\u00A0\u00A0\nschema:isPartOf<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Series\/alberta_ste_report<\/a>> ; # Alberta STE report.<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell\/Beta-Thalassemia, sickle cell\/Hemoglobin C disease and severe combined immunodeficiency : costs and cost analysis<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:productID<\/a> \"1048246242<\/span>\" ;\u00A0\u00A0\u00A0\nschema:url<\/a> <https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493557<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493557\/<\/a>> ;\u00A0\u00A0\u00A0\nschema:workExample<\/a> <http:\/\/worldcat.org\/isbn\/9781926929651<\/a>> ;\u00A0\u00A0\u00A0\nwdrs:describedby<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/1048246242<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Related Entities<\/h3>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Organization\/institute_of_health_economics<\/a>> # Institute of Health Economics,<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Organization<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Institute of Health Economics,<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Place\/alberta<\/a>> # Alberta.<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Place<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Alberta.<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Series\/alberta_ste_report<\/a>> # Alberta STE report.<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:PublicationSeries<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/www.worldcat.org\/oclc\/1048246242<\/a>> ; # Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell\/Beta-Thalassemia, sickle cell\/Hemoglobin C disease and severe combined immunodeficiency : costs and cost analysis<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"Alberta STE report.<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Alberta STE report<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/anemia_hemolytic_congenital_diagnosis<\/a>> # Anemia, Hemolytic, Congenital--diagnosis<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Anemia, Hemolytic, Congenital--diagnosis<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/brain_diseases_metabolic_inborn_diagnosis<\/a>> # Brain Diseases, Metabolic, Inborn--diagnosis<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Brain Diseases, Metabolic, Inborn--diagnosis<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/cost_benefit_analysis<\/a>> # Cost-Benefit Analysis<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Cost-Benefit Analysis<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/dried_blood_spot_testing_economics<\/a>> # Dried Blood Spot Testing--economics<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Dried Blood Spot Testing--economics<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/neonatal_screening_economics<\/a>> # Neonatal Screening--economics<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Neonatal Screening--economics<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/5375842389#Topic\/technology_assessment_biomedical<\/a>> # Technology Assessment, Biomedical<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Technology Assessment, Biomedical<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/id.loc.gov\/vocabulary\/countries\/abc<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:Place<\/a> ;\u00A0\u00A0\u00A0\ndcterms:identifier<\/a> \"abc<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/worldcat.org\/isbn\/9781926929651<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:ProductModel<\/a> ;\u00A0\u00A0\u00A0\nschema:isbn<\/a> \"1926929659<\/span>\" ;\u00A0\u00A0\u00A0\nschema:isbn<\/a> \"9781926929651<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/1048246242<\/a>>\u00A0\u00A0\u00A0\u00A0a \ngenont:InformationResource<\/a>, genont:ContentTypeGenericResource<\/a> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/www.worldcat.org\/oclc\/1048246242<\/a>> ; # Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell\/Beta-Thalassemia, sickle cell\/Hemoglobin C disease and severe combined immunodeficiency : costs and cost analysis<\/span>\n\u00A0\u00A0\u00A0\nschema:dateModified<\/a> \"2019-12-19<\/span>\" ;\u00A0\u00A0\u00A0\nvoid:inDataset<\/a> <http:\/\/purl.oclc.org\/dataset\/WorldCat<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Content-negotiable representations<\/p>\n